Teen acne awareness web site launched

Posted on September 30, 2008
Filed Under Acne | Leave a Comment

Sanofi-Aventis U.S. has teamed up with “Hannah Montana” television star Cody Linley and Dr. Jessica Wu, a dermatologist at Los Angeles County-USC Medical Center and clinical instructor at the University of Southern California School of Medicine, Los Angeles, to launch a teen acne awareness program and Web site (www.acneheroes.com). (Source: Pediatric News)

Treatments for acne, beginning with touch

Posted on September 30, 2008
Filed Under Acne | Leave a Comment

STANFORD, CALIF. — The art and science of treating acne in adolescents start with touching the patient. “Many adolescents have a feeling that their acne is very dirty, and they take it personally,” Dr. Alfred T. Lane said at a pediatric update sponsored by Stanford (Calif.) University. (Source: Pediatric News)

 

MedWorm Sponsored Message: Find out how you can get your message across here by sponsoring this MedWorm news feed.

[rosacea fulminans in the early course of a pregnancy by in vitro fertilization with embryo transfer.]

Posted on September 30, 2008
Filed Under Acne | Leave a Comment

We report a case of rosacea fulminans occurring at the onset of pregnancy and discuss a possible triggering role of endocrine factors, as well as therapeutic options. CASE REPORT: A 32-year-old woman with no previous history of dermatological disease consulted for rosacea fulminans appearing within the first three weeks of her first pregnancy, which required hormonal stimulation with recombinant FSH (follitropin alpha, Gonal F((R))) and an LHRH inhibitor (cetrorelix, Cetrotide((R))). She did not use topical corticosteroids or any other medication and had no other abnormalities at clinical examination. The skin disease lasted throughout pregnancy despite different treatments. After delivery, moderate improvement was observed within two weeks. Treatment with isotretinoin 0.5mg/kg/day was sta...

Treatment of acne using a 3-milligram drospirenone/20-microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen: a randomized controlled trial.

Posted on September 30, 2008
Filed Under Acne | Leave a Comment

Related Articles

Treatment of Acne Using a 3-Milligram Drospirenone/20-Microgram Ethinyl Estradiol Oral Contraceptive Administered in a 24/4 Regimen: A Randomized Controlled Trial.

Obstet Gynecol. 2008 Oct;112(4):773-781

Authors: Maloney JM, Dietze P, Watson D, Niknian M, Lee-Rugh S, Sampson-Landers C, Korner P

OBJECTIVE: To assess the efficacy of the combined oral contraceptive containing 3-mg drospirenone/20-microgram ethinyl estradiol (3-mg drospirenone/20-microgram ethinyl estradiol) administered as 24 consecutive days of active treatment after a 4-day hormone-free interval (24/4 regimen) compared with placebo for the treatment of moderate acne vulgaris. METHODS: Healthy females aged 14-45 years with moderate acne were randomized in this double-blind study to 3-mg drospirenone/20-microgram ethinyl estradiol (n=270) or placebo (n=268) for six cycles of 28 days. The primary outcome measures of acne lesion counts and Investigator Static Global Assessment scale ratings were assessed at baseline and during cycles 1, 3, and 6. RESULTS: The percentage reduction from baseline to endpoint for total lesions is 46.3% for 3-mg drospirenone/20-microgram ethinyl estradiol 24/4 combination oral contraceptive group and 30.6% for placebo group (P<.001). The likelihood of participants in the 3-mg drospirenone/20-microgram ethinyl estradiol 24/4 regimen group having "clear" or "almost clear" skin as rated by the investigators at endpoint was about threefold (odds ratio 3.13, 95% confidence interval 1.69-5.81; P=.001) greater than in the placebo group. The 3-mg drospirenone/20-microgram ethinyl estradiol 24/4 regimen was well tolerated. CONCLUSION: The low-dose combined oral contraceptive containing 3-mg drospirenone/20-microgram ethinyl estradiol administered in a 24/4 regimen significantly reduced acne lesion counts more effectively than placebo and demonstrated greater improvement in the Investigator Static Global Assessment rating of acne. The safety profile was consistent with low-dose combined oral contraceptive use. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, www.clinicaltrials.gov, NCT00651469 LEVEL OF EVIDENCE: I.

PMID: 18827119 [PubMed - as supplied by publisher]

(Source: Obstetrics and Gynecology)

Homemade Teen and Adult Acne Skin Treatment – Nature Works

Posted on September 30, 2008
Filed Under Acne | Leave a Comment

Teenage Acne keep looking »